Skip to content

A Patient and Family Questionnaire Survey on Satisfaction with Lecanemab Treatment and Its Related Factors

A Questionnaire Study on Subjective Satisfaction with Lecanemab Treatment and Its Contributing Factors Among Patients with Early Alzheimer's Disease and Their Family Care Partners - Lecanemab Treatment Satisfaction and Factors Analysis Survey

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000060988
Enrollment
120
Registered
2026-03-20
Start date
2026-03-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Alzheimer&#39

Interventions

None listed

Sponsors

Eisai Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patient 1)First-time respondent to this study questionnaire 2)Diagnosed with early AD and initiated lecanemab treatment 3)At least 6 months have passed since lecanemab treatment initiation 4)Written informed consent obtained based on the patient's free will 5)Age 18 years or older Family care partner 1)First-time respondent to this study questionnaire 2)Provides daily support or caregiving to an eligible patient 3)Written informed consent obtained 4)Age 18 years or older

Exclusion criteria

Exclusion criteria: Patient Unable to complete the questionnaire by themselves or via designated family assistance Family care partner Unable to complete the questionnaire

Design outcomes

Primary

MeasureTime frame
Treatment satisfaction among patients and their family care partners

Secondary

MeasureTime frame
Treatment understanding, treatment engagement, perceived treatment effects, other concerns (including aspects of the patient's daily functioning), and qualitative responses (free-text) among family care partners.

Countries

Japan

Contacts

Public ContactMariko Endo

Eisai Co., Ltd Medical Headquarters, Neurology Department

m4-endo@hhc.eisai.co.jp03-3817-3700

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026